Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Abstract

OPINION STATEMENT The development of tyrosine kinase inhibitors (TKIs) dramatically changed the treatment landscape for many different cancers including chronic myeloid leukemia (CML). With the introduction of imatinib, the first TKI developed and approved to effectively treat CML, patient survival has increased dramatically and, in some cases, this fatal… (More)
DOI: 10.1007/s11936-017-0524-8

1 Figure or Table

Topics

  • Presentations referencing similar topics